Managerial Unionism and the Law in New Zealand

This paper examines the issue of trade unionism amongst the fastest growing occupational group in New Zealand, which is also the least unionised, managers and administrators. Despite facing similar threats to employment security and changes to working conditions as other wage and salary earners, most managers and administrators do not have the benefits of a protective organisation to bargain on their behalf. The paper examines forms of collective representation for managers, but particularly incorporation and registration as a trade union. Problems associated with attempts to register managerial unions are discussed, and the particular case of APEX is examined. The paper concludes with some suggestions for changes to the law to ease the plight of those managers who wish to unionise, and summarises the current avenues available for collective representation

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Preliminary results of CoQtz-N: A quartz reference material for terrestrial in-situ cosmogenic 10Be and 26Al measurements

There is growing interest in geochronological applications of terrestrial in situ-produced cosmogenic nuclides, with the most commonly measured being 10Be and 26Al in quartz. To extract and then separate these radionuclides from quartz and prepare them in the oxide form suitable for accelerator mass spectrometry (AMS) requires extensive and careful laboratory processing. Here we discuss the suitability of a crushed, sieved and etched, sub-aerially exposed vein quartz specimen (CoQtz-N) to act as a reference material for chemical laboratory preparation and AMS measurements. Splits of CoQtz-N were distributed to eleven target preparation laboratories. The CoQtz-N 10Be targets were then measured at seven different AMS facilities and five of the preparation laboratories had their 26Al targets measured at four different AMS facilities. We show that CoQtz-N splits are sufficiently homogeneous with regard to nuclide concentrations, that it has been cleaned of any atmospheric derived (i.e. meteoric) 10Be and that it has low concentrations of the major elements that can interfere with Be and Al extraction chemistry and AMS measurements. We derive preliminary concentrations for 10Be and 26Al in CoQtz-N as 2.53 ± 0.09 x 106 at/g and 15.6 ± 1.6 x 106 at/g, respectively, at the 95% confidence limit

Search for the standard model Higgs boson at LEP

The four LEP Collaborations, ALEPH, DELPHI, L3 and OPAL, have collected a total of 2461 pb(-1) of e(+)e(-) collision data at centre-of-mass energies between 189 and 209 GeV. The data are used to search for the Standard Model Higgs boson. The search results of the four Collaborations are combined and examined in a likelihood test for their consistency with two hypotheses: the background hypothesis and the signal plus background hypothesis. The corresponding confidences have been computed as functions of the hypothetical Higgs boson mass. A lower bound of 114.4 GeV/c(2) is established, at the 95% confidence level, on the mass of the Standard Model Higgs boson. The LEP data are also used to set upper bounds on the HZZ coupling for various assumptions concerning the decay of the Higgs boson. (C) 2003 Elsevier B.V. All rights reserved